23.03.2016 17:45:00

Moody's: Hepatitis-C patent ruling negative for Gilead

New York, March 23, 2016 -- Moody's Investors Service commented that a recent jury decision in favor of Merck & Co., Inc. (A1 stable) and against Gilead Sciences, Inc. (A3 positive) related to hepatitis-C patents is credit negative for Gilead. There is currently no impact on Gilead's A3 rating or positive rating outlook.

Vollständigen Artikel bei Moodys lesen